Mackenzie Financial Corp Lowers Holdings in Amgen Inc. (NASDAQ:AMGN)

Mackenzie Financial Corp lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,192 shares of the medical research company's stock after selling 2,646 shares during the quarter. Mackenzie Financial Corp's holdings in Amgen were worth $43,577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Centricity Wealth Management LLC bought a new position in Amgen in the 4th quarter valued at $25,000. Pinney & Scofield Inc. bought a new position in Amgen in the 4th quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE grew its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in Amgen in the 4th quarter valued at $34,000. Finally, Atala Financial Inc bought a new position in Amgen in the 4th quarter valued at $34,000. Institutional investors own 76.50% of the company's stock.

Amgen Trading Up 1.8%

Shares of NASDAQ AMGN traded up $5.14 during mid-day trading on Thursday, hitting $283.54. The stock had a trading volume of 2,800,923 shares, compared to its average volume of 2,801,330. The business has a 50 day moving average price of $284.48 and a two-hundred day moving average price of $285.76. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $152.46 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.96 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.36%. Amgen's dividend payout ratio is presently 86.86%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. Royal Bank of Canada reduced their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler decreased their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Finally, Guggenheim began coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Amgen presently has an average rating of "Hold" and an average target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.